{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-005554","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.670427+00:00","generated_at":"2026-06-18T22:30:57.243197+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lyell Immunopharma Q4 net loss $8.4M, revenue $48.4M; cash $710.3M","bullets":["Q4 2022 net loss $8.4M (vs $83.7M Q4 2021); full year net loss $183.1M (vs $250.2M).","Revenue $48.4M in Q4 2022, up from $2.8M in Q4 2021, driven by GSK collaboration deferred revenue.","Cash, cash equivalents and marketable securities $710.3M as of Dec 31, 2022; cash runway into 2026.","Phase 1 trials ongoing for LYL797 (ROR1 CAR T) and LYL845 (TIL); initial data expected in 2024.","Lynn Seely named President and CEO in Dec 2022; Rahsaan Thompson CLO; Gary Lee CSO."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-005554","json":"https://secwatch.observer/filing/0001628280-23-005554.json","markdown":"https://secwatch.observer/filing/0001628280-23-005554.md","text":"https://secwatch.observer/filing/0001628280-23-005554.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023005554/0001628280-23-005554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023005554/lyel-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:30:57.243197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34333e367f9ddde7605ece652a9163a80a27a58e","claim":"Lyell Immunopharma, Inc. reported the year ended December 31, 2022 results: net income $183.1 million.","evidence_excerpt":"Lyell reported a net loss of $8.4 million and $183.1 million for the fourth quarter and year ended December 31, 2022,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023005554/0001628280-23-005554-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$183.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c8087b7800f6d0913e15150f7f2c5a28a1f82f06","claim":"Lyell Immunopharma, Inc. reported the fourth quarter ended December 31, 2022 results: net income $8.4 million.","evidence_excerpt":"Lyell reported a net loss of $8.4 million and $183.1 million for the fourth quarter and year ended December 31, 2022,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023005554/0001628280-23-005554-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Net income","value":"$8.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}